Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Binds virus or component thereof
Reexamination Certificate
2008-01-29
2008-01-29
Chen, Stacy B. (Department: 1648)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Binds virus or component thereof
C424S211100
Reexamination Certificate
active
07323172
ABSTRACT:
The present invention encompasses novel antibodies and fragments thereof which immunospecifically bind to one or more RSV antigens and compositions comprising said antibodies and antibody fragments. The present invention encompasses methods preventing respiratory syncytial virus (RSV) infection in a human, comprising administering to said human a prophylactically effective amount of one or more antibodies or fragments thereof that immunospecifically bind to one or more RSV antigens, wherein a certain serum titer of said antibodies or antibody fragments is achieved in said human subject. The present invention also encompasses methods for treating or ameliorating symptoms associated with a RSV infection in a human, comprising administering to said human a therapeutically effective amount of one or more antibodies or fragments thereof that immunospecifically bind to one or more RSV antigens, wherein a certain serum titer of said antibodies or antibody fragments is achieved in said human subject. The present invention further encompasses compositions comprising antibodies or fragments thereof that immunospecifically bind to a RSV antigen, and methods using said compositions for detection or diagnosis a RSV infection.
REFERENCES:
patent: 4526938 (1985-07-01), Churchhill et al.
patent: 4880078 (1989-11-01), Inoue et al.
patent: 5128326 (1992-07-01), Balazs et al.
patent: 5290540 (1994-03-01), Prince et al.
patent: 5585089 (1996-12-01), Queen et al.
patent: 5679377 (1997-10-01), Bernstein et al.
patent: 5693762 (1997-12-01), Queen et al.
patent: 5811524 (1998-09-01), Brams et al.
patent: 5824307 (1998-10-01), Johnson
patent: 5840298 (1998-11-01), Brams et al.
patent: 5855913 (1999-01-01), Hanes et al.
patent: 5866125 (1999-02-01), Brams et al.
patent: 5874064 (1999-02-01), Edwards et al.
patent: 5912015 (1999-06-01), Bernstein et al.
patent: 5916597 (1999-06-01), Lee et al.
patent: 5934272 (1999-08-01), Lloyd et al.
patent: 5939068 (1999-08-01), Brams et al.
patent: 5955364 (1999-09-01), Brams et al.
patent: 5958765 (1999-09-01), Brams et al.
patent: 5985309 (1999-11-01), Edwards et al.
patent: 5985320 (1999-11-01), Edwards et al.
patent: 5989463 (1999-11-01), Tracy et al.
patent: 6019968 (2000-02-01), Platz et al.
patent: 6096551 (2000-08-01), Barbas et al.
patent: 6537809 (2003-03-01), Brams
patent: 2002/0001798 (2002-01-01), Brams et al.
patent: WO 91/05548 (1991-05-01), None
patent: WO 92/19244 (1992-11-01), None
patent: WO 96/05229 (1996-02-01), None
patent: WO 96/20698 (1996-07-01), None
patent: WO 97/32572 (1997-09-01), None
patent: WO 97/34631 (1997-09-01), None
patent: WO 97/44013 (1997-11-01), None
patent: WO 98/31346 (1998-07-01), None
patent: WO 99/15154 (1999-04-01), None
patent: WO 99/20253 (1999-04-01), None
patent: WO 99/66903 (1999-12-01), None
patent: WO 00/29584 (2000-05-01), None
Landry et al., (1999) “Evaluation of reconstituted lyophilized palivizumab given intravenously at 15 and 30 mg/kg,” Pediatric Research, 45 (4 Pt 2:166A, 969 Annual Meeting of the American Pediatric Society and the Society for Pediatric Research. San Francisco, California, USA. May 1-4, 1999 Poster Session (poster 87).
The IMpact-RSV Study Group (1998), “Palivizumab, A Humanized Respiratory Syncytial Virus Monoclonal Antibody, Reduces Hospitalization From Respiratory Syncytial Virus Infection in High-Risk Infants,” Pediatrics 102(3 Pt 1):531-537.
Mejias et al. (2005) “Respiratory syncytial virus infections: Old challenges and new opportunities,” Ped. Infect. Dis. J. 24:S189-S197).
“MedImmune, Inc.'s (MEDI) phase 1 Numax™ study shows potential to reduce RSV disease in upper airway of children.” (Sep. 1, 2005) BioSpace Beat, Biospace.com (www.biospace.com
ews—story.aspx?StoryID=21014020).
MedImmune, Inc. (MEDI) Release: Numax® achieves primary endpoint in preliminary analysis of data from comparative phase 3 trial with Synagis® (Nov. 6, 2006)BioSpace Beat, www.biospace.com. (www.biospace.com
ews—story.aspx?StoryID=36114&full=1).
“Motavizumab vs. palivizumab for RSV infections in infants” (Nov. 11, 2006)Inpharmavol. 1 No. 1563, p. 5.
U.S. Appl. No. 09/158,120, filed Sep. 21, 1998, “Human-Murine Chimeric Antibodies Against Respiratory Syncytial Virus”.
U.S. Appl. No. 09/865,499, filed May 25, 2001, “Epitope Based Vaccine for Respiratory Syncytial Virus F-Protein”.
U.S. Appl. No. 09/848,390, filed May 3, 2001, “Combination Therapy of Respiratory Diseases using Antibodies”.
U.S. Appl. No. 09/848,377, filed May 3, 2001, “Combination Therapy of Respiratory Diseases Using Antibodies and Anti-Inflammatory Agents”.
U.S. Appl. No. 09/797,760, filed Mar. 2, 2001, “Methods of Enhancing Activity of Vaccines and Vaccine Compositions”.
U.S. Appl. No. 09/796,848, filed Mar. 1, 2001, “High Potency Recombinant Antibodies and Methods for Producing Them”.
U.S. Appl. No. 09/781,052, filed Feb. 9, 2001, “Antibody Gene Therapy with Adeno-Associated Viral Vectors”.
U.S. Appl. No. 09/771,415, filed Jan. 26, 2001, “Ultra High Affinity Neutralizing Antibodies”.
U.S. Appl. No. 60/186,252, filed Mar. 1, 2000, “High Potency Recombinant Antibodies and Methods for Producing Them”.
U.S. Appl. No. 60/168,426, filed Nov. 30, 1999, “High Potency Recombinant Antibodies and Methods for Producing Them”.
Hacking et al., 2002, “Respiratory syncytial virus—viral biology and the host response,” J. Infection 45:18-24.
Heard et al., 1999, “Two neutralizing human RSV antibodies: cloning, expression, and characterization,” Mol. Med. 5:35-45.
Saez-Llorens et al., 1997, “Phase I/II open label multi dose escalation trial of a humanized respiratory synctial virus (RSV) monoclonal antibody (Medi-493) administered intramuscularly (IM) in high risk children,” Abstracts in Non HIV virology, ICAAC Toronto.
Subramanian et al., 1997, “Randomized double blind placebo controlled dose escalation trial of a humanized respiratory synctial virus monoclonal antibody in hugh risk infants,” Poster session infect. dis. 130A:768.
Sorbera et al., 1998, “Palivizumab,” Drugs of the Future 23:970-976.
Sorbera et al., 1998, “Palivizumab,” Drugs Data Report 20:702-703.
Anderson et al., 1985, “Microneutralization test for respiratory syncytial virus based on an enzyme immunoassay,” J. Clin. Microbiol. 22:1050-1052.
Boulianne et al., 1984, “Production of functional chimaeric mouse/human antibody,” Nature 312(5995):643-646.
Carson et al., 1986, “Human lymphocyte hybridomas and monoclonal antibodies,” Adv. Immunol. 38:275-311.
Conrad et al., 1987, “Aerosolized ribavirin treatment of respiratory syncytial virus infection in infants hospitalized during an epidemic,” Pediatr. Infect. Dis. J. 6(2):152-158.
Cruse et al., 1995, Illustrated Dictionary of Immunology, Boca Raton: CRC Press, pp. 18-19.
Dorland's Illustrated Medical Dictionary, 1994, 28thed., Philadelphia: WB Saunders p. 874.
Duenas et al., 1996, “In vitro immunization of naïve human B cells yields high affinity immunoglobulin G antibodies as illustrated by phage display,” Blackwell Science Limited, pp. 1-7.
Duenas et al., 1996, “Selection of phage displayed antibodies based on kinetic constants,” 33(3):279-285.
Everitt et al., 1996, “The pharmacokinetics, antigenicity, and fusion-inhibition activity of RSHZ19, a humanized monoclonal antibody to respiratory syncytial virus, in healthy volunteers,” J. Infect. Dis.
Foote et al., 1995, “Kinetic and affinity limits on antibodies produced during immune response,” Proc. Nat'l Acad. Science USA 92:1254-1256.
Foote et al., 1991, “Kinetic maturation of an immune response,” Nature vol. 352.
Glaser et al., 1992, “Antibody engineering by codon-based mutagenesis in a filamentous phage vector system,”
Huse William D.
Johnson Leslie S.
Koenig Scott
Watkins Jeffrey D.
Wu Herren
Chen Stacy B.
Jones Day
MedImmune, Inc.
LandOfFree
Methods of administering/dosing anti-RSV antibodies for... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of administering/dosing anti-RSV antibodies for..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of administering/dosing anti-RSV antibodies for... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2749009